Huaren Pharmaceutical (300110.SZ) has dismissed Hong Liang from the position of CEO.
Huarun Pharmaceutical (300110.SZ) announced that the company will hold the eighth session of the board of directors on December 27, 2024.
Huaren Pharmaceutical (300110.SZ) issued an announcement, stating that on December 27, 2024, the company held the sixth (interim) meeting of the eighth board of directors, where they approved the motion for the dismissal of the company's CEO. According to the company's needs for operational management, and after review by the board of directors' nomination committee, the board of directors agreed to dismiss Mr. Hong Liang from his position as CEO, with the dismissal taking effect from the date of the board meeting. After the dismissal, Mr. Hong Liang will no longer hold any position within the company, and this dismissal will not have any adverse effects on the company's normal operational activities.
Related Articles
DINGDANG HEALTH (09886) purchased approximately 99,500 shares for around HK$105,400 on December 31st.
CHANJET (01588) spent 39,500 Hong Kong dollars on December 31 to repurchase 5000 shares.
KAM HING INTERNATIONAL (02307): Li Xiangmin Resigns as Non-executive Director
DINGDANG HEALTH (09886) purchased approximately 99,500 shares for around HK$105,400 on December 31st.
CHANJET (01588) spent 39,500 Hong Kong dollars on December 31 to repurchase 5000 shares.
KAM HING INTERNATIONAL (02307): Li Xiangmin Resigns as Non-executive Director
